2024 年至 2031 年分子生物学酵素、试剂盒和试剂市场（按产品、应用、最终用户和地区划分）

分子生物学酵素、试剂盒和试剂市场评估，2024 年至 2031 年

对增强诊断程序和个人化治疗的需求不断增长，推动了分子生物学酶、试剂盒和试剂市场的发展。据 Verified Market Research 分析师称，分子生物学酶、试剂盒和试剂市场预计将从 2023 年的 193 亿美元下降，到 2031 年预测期内达到 694 亿美元的估值。

受全球阐明复杂生物过程和疾病机制的雄心推动，基因组学和蛋白​​质组学研究蓬勃发展，从而推动了对分子生物学酶、试剂盒和试剂的需求。需求激增将推动市场在 2024 年至 2031 年期间以 17.35% 的复合年增长率成长。

分子生物学酶、试剂盒和试剂市场的定义/概述

分子生物学酵素、试剂盒和试剂是用于操作和分析 DNA、RNA 和蛋白质的专门生化工具。这些工具包括酶，例如 DNA 聚合酶（可扩增 DNA）、限制性内切酶（可在特定区域切割 DNA）和连接酶（可将 DNA 片段连接在一起）。试剂盒和试剂包括执行分子生物学程序所需的组件，例如 PCR（聚合酶炼式反应）以扩增 DNA、凝胶电泳以分离 DNA 以及定序以确定 DNA 中碱基的顺序。

此外，这些产品对于各种应用至关重要，包括基因研究、医学诊断、法医分析和治疗开发，使科学家和临床医生能够研究疾病的分子原因，识别基因突变，并允许有针对性的治疗得到发展。

推动市场成长的关键因素有哪些？

基因组学和蛋白​​质组学研究的快速进步极大地促进了分子生物学酶、试剂盒和试剂市场的发展。定序、CRISPR 等基因编辑技术以及蛋白质体学研究的技术进步正在拓宽分子生物学酶的应用并促进市场扩张。这些突破使得人们能够精确地识别基因变化和蛋白质，促进个人化医疗和生物技术创新的发展。

对个人化医疗日益增长的需求是市场的主要驱动力。个人化医疗利用基因和蛋白质组学数据来为特定患者制定治疗方案，需要在诊断、治疗标靶发现和药物开发中使用分子生物学酶和试剂盒。这项策略提高了治疗效果，同时减少了副作用，促进了分子生物学产品在医疗保健领域的应用。

此外，生物製药产业的兴起是推动分子生物学酶、试剂盒和试剂需求的主要因素。这些工具对于生物製药（包括治疗性蛋白质和核酸类产品）的研究、开发和生产至关重要。生物製药研发支出的不断增加以及药物开发管道中生物製剂数量的不断增加，推动了对高品质分子生物学产品的需求市场不断增长。

阻碍市场成长的主要课题是什么？

酵素、试剂盒和试剂必需品质高且可重复，以提供可靠的研究和临床结果。然而，製造流程、原料品质和储存条件的变化都会影响产品的一致性。由于分子生物学应用需要较高的特异性和灵敏度，其复杂性日益增加，这进一步加剧了这项课题。解决这些问题需要严格的品质控管程序、协议标准化和验证流程，所有这些都会增加製造成本并限制这些关键仪器的可用性，从而阻碍市场需求。

监理合规是进入市场的一大障碍。用于诊断、药物研究和治疗应用的产品必须符合美国食品药物管理局 (FDA) 和欧洲药品管理局 (EMA) 等组织制定的严格监管要求。获得批准既费时又费钱，会延迟产品发布、增加开发成本并限制市场准入。

目录

第 1 章全球分子生物学酵素、试剂盒与试剂市场简介

市场概况
• 研究范围
• 先决条件

第 2 章执行摘要

第 3 章：经过验证的市场研究方法

• 资料探勘
• 验证
• 主要来源
• 资料来源列表

第 4 章 分子生物学酵素、试剂盒与试剂的全球市场展望

• 概述
• 市场动态
  • 驱动程式
  • 阻碍因素
  • 机会
• 波特五力模型
• 价值链分析

5. 全球分子生物学酵素、试剂盒与试剂市场（依应用）

• 概述
• 聚合酶炼式反应 (PCR)
• 排序
• 克隆 表观遗传学
• 限制性酵素消化
• 合成生物学
• 其他

6. 全球分子生物学酵素、试剂盒和试剂市场（依产品划分）

• 概述
• 试剂盒和试剂
• 酶
• 聚合酶
• 连接酶
• 其他

7. 全球分子生物学酵素、试剂盒和试剂市场（依最终用户划分）

• 概述
• 学术和研究机构
• 製药和生技公司
• 医院和诊断中心
• 其他

8. 全球分子生物学酵素、试剂盒和试剂市场（按地区）

• 概述
• 北美洲
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 其他欧洲国家
  亚太地区
  • 中国
  • 日本
  • 印度
  • 其他亚太地区
• 世界其他地区
  • 拉丁美洲
  • 中东和非洲

9. 全球分子生物学酵素、试剂盒与试剂市场：竞争格局

• 概述
• 各公司的市场排名
• 主要发展策略

第十章 公司简介

• Thermo Fisher Scientific Inc
• Illumina
• Qiagen
• Agilent Technologies
• F. Hoffmann-La Roche Ltd.
• Merck KGaA
• Jena Bioscience GmbH
• Bioline Technologies
• Promega Corporation
• Rockland Immunochemicals Inc

第 11 章 重大进展

• 产品发布/开发
• 合併和收购
• 业务扩展
• 伙伴关係和合作关係

第 12 章附录

• 相关研究

Molecular Biology Enzymes And Kits And Reagents Market Valuation - 2024-2031

The growing demand for enhanced diagnostic procedures and personalized treatment is driving the Molecular Biology Enzymes And Kits And Reagents Market. According to the analyst from Verified Market Research, the Molecular Biology Enzymes And Kits And Reagents Market is estimated to reach a valuation of USD 69.4 Billion over the forecast period 2031, subjugating around USD 19.3 Billion in 2023.

The boom in genomic and proteomic research efforts, fueled by the global ambition to comprehend complex biological processes and disease mechanisms, is driving up demand for molecular biology enzymes, kits, and reagents. This surge in demand enables the market to grow at a CAGR of 17.35% from 2024 to 2031.

Molecular Biology Enzymes And Kits And Reagents Market: Definition/ Overview

Molecular biology enzymes, kits, and reagents are specialized biochemical instruments for manipulating and analyzing DNA, RNA, and proteins. These tools include enzymes such as DNA polymerases, which amplify DNA, restriction endonucleases, which cut DNA at specified regions, and ligases, which combine DNA fragments, among others. Kits and reagents contain the components required to perform molecular biology procedures such as PCR (polymerase chain reaction) for DNA amplification, gel electrophoresis for DNA separation, and sequencing to determine the order of DNA bases.

Furthermore, these products are essential in various applications, including genetic research, medical diagnostics, forensic analysis, and therapeutic development, allowing scientists and clinicians to investigate the molecular causes of diseases, identify genetic variations, and develop targeted treatments.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

What are the Key Drivers that Bolster the Market Growth?

Rapid advances in genomics and proteomics research have considerably boosted the molecular biology enzymes, kits, and reagents market. Technological advancements in sequencing technologies, gene editing techniques such as CRISPR, and proteomics studies have broadened the applications of molecular biology enzymes, driving market expansion. These breakthroughs allow for precise genetic changes and protein identification, promoting the development of personalized medicine and biotechnological innovations.

The growing need for personalized medication has become a key market driver. Personalized medicine uses genetic and proteomic data to personalize treatments for specific patients, necessitating the use of molecular biology enzymes and kits in diagnostics, therapeutic target discovery, and drug development. This strategy improves therapy efficacy while reducing negative effects, encouraging the use of molecular biology products in healthcare.

Furthermore, the rise of the biopharmaceutical industry is a key factor driving demand for molecular biology enzymes, kits, and reagents. These tools are required for the study, development, and manufacture of biopharmaceuticals, such as therapeutic proteins and nucleic acid-based products. The increased expenditure in biopharmaceutical R&D, together with the growing number of biologics in the drug development pipeline, boosting the expansion of the market by needing high-quality molecular biology products.

What are the Primary Challenges Hindering the Growth of the Market?

Enzymes, kits, and reagents must be of high quality and reproducible to provide trustworthy research and clinical results. However, variability in the manufacturing process, raw material quality, and storage conditions all have an impact on product consistency. This difficulty is exacerbated by the growing complexity of molecular biology applications that require high specificity and sensitivity. Addressing these concerns necessitates stringent quality control procedures, protocol standardization, and validation processes, all of which raise manufacturing costs limit the availability of these vital instruments and inhibit market expansion.

Regulatory compliance presents a substantial barrier for the market. Products used in diagnostics, medication research, and therapeutic applications must adhere to high regulatory requirements established by organizations such as the United States Food and Medication Administration (FDA) and the European Medicines Agency. Obtaining approvals is time-consuming and expensive, delaying product releases, increasing development expenses and restricting market growth.

Category-Wise Acumens

Is Kits and Reagents Segment Dominating the Product Category?

According to VMR analysis, the kits and reagents segment is estimated to hold the largest market share in the product segment during the forecast period. Kits and reagents are required for a variety of molecular biology techniques, such as PCR, sequencing, cloning, and gene expression studies. Their adaptability and integration into multiple processes make them essential for ordinary and specialized research jobs. This broad applicability drives demand in a variety of disciplines, including academic research, clinical diagnostics, drug discovery, and development, contributing to their significant market share.

Kits and reagents are intended to simplify difficult molecular biology processes, lowering the time and technical skill required to conduct research. They frequently include pre-measured components and precise protocols to reduce errors and variability, improving repeatability and efficiency in the lab. This convenience, combined with the promise of consistent results, appeals to both seasoned researchers and those new to molecular biology, increasing adoption and market dominance.

Furthermore, the expanding emphasis on genomic research, driven by efforts to understand the genetic basis of diseases and develop personalized therapy, is resulting in a major increase in demand for high-quality kits and reagents. These items are essential for analyzing genetic data, identifying biomarkers, and creating tailored medicines. The growth of personalized medicine, which uses genetic information to customize therapies to specific patients, is increasing the demand for dependable and efficient kits and reagents, reinforcing their market position.

What are the Key Driving Forces for the Dominance of the PCR Application Segment?

The polymerase chain reaction (PCR) segment is estimated to dominate the Molecular Biology Enzymes And Kits And Reagents Market during the forecast period. PCR is a fundamental technique used in genetic and molecular research, as well as diagnostic applications such as infectious disease detection, cancer research, and genetic testing. The COVID-19 pandemic highlighted the critical role of PCR in quick testing and diagnostics, resulting in an unprecedented rise in demand for PCR kits and reagents. Its versatility and capacity to quickly amplify tiny pieces of DNA or RNA make it essential in both clinical and scientific settings.

Continuous advances in PCR technologies, such as real-time PCR (qPCR) and digital PCR (dPCR), have extended applications while improving sensitivity, specificity, and throughput. These advancements have simplified the application of PCR in a variety of disciplines, including personalized medicine, where it is utilized for patient stratification and disease progression monitoring, resulting in increased demand for PCR-related products.

Furthermore, the trend to precision medicine, as well as the growing demand for genetic testing for inherited illnesses, pharmacogenomics, and disease risk assessment, has accelerated the usage of PCR. PCR's capacity to detect specific DNA sequences makes it indispensable in various applications, adding to its market dominance. The growing awareness and acceptance of personalized healthcare solutions has resulted in increased investment in R&D activities in this area, which has fueled the rise of the PCR segment.

Country/Region-wise Acumens

Will Flourishing Healthcare Industry in North America Fuel this market?

According to VMR analyst, North America is estimated to dominate the Molecular Biology Enzymes And Kits And Reagents Market during the forecast period. The United States, in particular, provides substantial public and private financing for healthcare and biological research. The National Institutes of Health (NIH) and the Biomedical Advanced Research and Development Authority (BARDA), as well as private organizations and pharmaceutical firms, all offer significant financing for genetics, molecular biology, and related research. This financial support is driving up demand for molecular biology goods and helps to build the market.

Furthermore, North America is home to some of the world's largest biotechnology and pharmaceutical industries, which rely heavily on molecular biology enzymes, kits, and reagents. These industries deal with drug research, development, and diagnostic test development, all of which rely significantly on molecular biology techniques. The concentration of these businesses in North America, together with their innovation capabilities and market size, fueling the demand and development of advanced molecular biology products.

What are the Factors Leading to a Significant Share in Europe?

Europe has been in the lead in implementing precision medicine efforts and large-scale genomic projects. Countries such as the United Kingdom's 100,000 Genomes Project and France's National Genomic Medicine Strategy 2025 strive to integrate genomics into their healthcare systems. These projects necessitate considerable use of molecular biology products for DNA sequencing, PCR, and other genomic technologies, resulting in market expansion in the region.

Furthermore, European countries have made considerable investments in life sciences and biotechnology research, including both public and commercial funding. Horizon Europe, is the EU's primary funding program for research and innovation, with a budget of approximately €100 billion for the years 2021-2027, demonstrating the region's commitment to advancing scientific and technical research, including molecular biology. These expenditures increase the need for molecular biology enzymes, kits, and reagents required for cutting-edge research and development operations.

Competitive Landscape

The Molecular Biology Enzymes, and Kits and Reagents Market is characterized by a dynamic competitive landscape, driven by rapid advances in biotechnology and rising demand for molecular biology applications in a variety of industries, including healthcare, research, and diagnostics. The emphasis on precision and reliability, combined with severe regulatory requirements, influences the competitive strategies of businesses in this market.

Some of the prominent players operating in the Molecular Biology Enzymes And Kits And Reagents Market include:

Thermo Fisher Scientific Inc, Illumina, Qiagen, Agilent Technologies, F. Hoffmann-La Roche Ltd., Merck KGaA, Jena Bioscience GmbH, Bioline Technologies, Promega Corporation, Rockland Immunochemicals Inc, Takara Bio Inc, New England Biolabs Inc., Lucigen Corporation, GE Healthcare, PerkinElmer Inc., Bio-Rad Laboratories, Abbott Laboratories.

Latest Developments

In February 2024, Agilent Technologies announced the release of its new SureSelectXT Target Enrichment Kit for Illumina Sequencing, a comprehensive solution for targeted next-generation sequencing (NGS) library preparation.

In February 2024, Thermo Fisher Scientific announced a collaboration with Bio-Techne to create and commercialize new companion diagnostics for targeted cancer medicines.

In January 2024, Merck KGaA expanded its CRISPR portfolio with the introduction of new Cas9 enzymes and guide RNAs for gene editing applications.

In January 2024, Illumina announced the release of their new NovaSeq X Plus sequencing device, which provides higher throughput and accuracy for whole-genome and RNA sequencing applications.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL MOLECULAR BIOLOGY ENZYMES AND KITS AND REAGENTS MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL MOLECULAR BIOLOGY ENZYMES AND KITS AND REAGENTS MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL MOLECULAR BIOLOGY ENZYMES AND KITS AND REAGENTS MARKET, BY APPLICATION

• 5.1 Overview
• 5.2 Polymerase Chain Reaction (PCR)
• 5.3 Sequencing
• 5.4 Cloning
• 5.5 Epigenetics
• 5.6 Restriction Digestion
• 5.7 Synthetic Biology
• 5.8 Others

6 GLOBAL MOLECULAR BIOLOGY ENZYMES AND KITS AND REAGENTS MARKET, BY PRODUCT

• 6.1 Overview
• 6.2 Kits and Reagents
• 6.3 Enzymes
• 6.4 Polymerases
• 6.5 Ligases
• 6.6 Others

7 GLOBAL MOLECULAR BIOLOGY ENZYMES AND KITS AND REAGENTS MARKET, BY END-USER

• 7.1 Overview
• 7.2 Academic and Research Institutes
• 7.3 Pharmaceutical and Biotechnology Companies
• 7.4 Hospitals and Diagnostic Centers
• 7.5 Others

8 GLOBAL MOLECULAR BIOLOGY ENZYMES AND KITS AND REAGENTS MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.3 Canada
  • 8.2.4 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 Middle East and Africa

9 GLOBAL MOLECULAR BIOLOGY ENZYMES AND KITS AND REAGENTS MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Ranking
• 9.3 Key Development Strategies

10 COMPANY PROFILES

• 10.1 Thermo Fisher Scientific Inc
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 Illumina
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 Qiagen
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 Agilent Technologies
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 F. Hoffmann-La Roche Ltd.
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 Merck KGaA
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments
• 10.7 Jena Bioscience GmbH
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments
• 10.8 Bioline Technologies
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.9 Promega Corporation
  • 10.9.1 Overview
  • 10.9.2 Financial Performance
  • 10.9.3 Product Outlook
  • 10.9.4 Key Developments
• 10.10 Rockland Immunochemicals Inc
  • 10.10.1 Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Outlook
  • 10.10.4 Key Developments

11 KEY DEVELOPMENTS

• 11.1 Product Launches/Developments
• 11.2 Mergers and Acquisitions
• 11.3 Business Expansions
• 11.4 Partnerships and Collaborations

12 Appendix

• 12.1 Related Research